ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MAN vs ASTH // EV/EBITDA & P/E VALUATION

ManpowerGroup (NYSE) VS. Astrana Health Inc. (NASDAQ) • 15-METRIC TALLY: MAN 4 — ASTH 5
▲ EV/EBITDA & P/E VALUATION LEADER: MAN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MAN VS. ASTH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MAN ASTH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 16.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 5.30% 4.60% +0.70 MAN /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 15.3x 27.3x -12.00 MAN /valuation <GO>
Free Cash Flow Yield -4.92% 5.75% -10.67 ASTH /fcf-yield <GO>
Operating Margin 0.80% 2.50% -1.70 ASTH /operating-margins <GO>
Net Profit Margin — 0.80% — TIE /net-margins <GO>
Revenue Growth (YoY) 0.60% 56.40% -55.80 ASTH /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 3.15% 0.43% +2.72 MAN /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.54 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 6/9 -4.00 ASTH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.4 46.7 -6.37 ASTH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 63.6x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.12B $1.82B $299.0M MAN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MAN REV ASTH REV MAN GROSS % ASTH GROSS % MAN FCF ASTH FCF
FY 2025 $17.96B $3.18B 16.7% — -$104.1M $104.5M
FY 2024 $17.85B $2.03B 17.3% — $309.2M $44.2M
FY 2023 $18.91B $1.39B — — $348.2M $68.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MAN // BETA —
ASTH // BETA —